|1.||Yuan, Chun-Su: 13 articles (02/2014 - 01/2002)|
|2.||Moss, Jonathan: 9 articles (08/2015 - 12/2003)|
|3.||Israel, Robert J: 9 articles (07/2015 - 05/2006)|
|4.||Stambler, Nancy: 6 articles (02/2012 - 05/2008)|
|5.||Singleton, Patrick A: 5 articles (08/2015 - 06/2008)|
|6.||Wang, Chong-Zhi: 5 articles (02/2014 - 01/2009)|
|7.||Paterson, Craig: 4 articles (01/2016 - 01/2015)|
|8.||Forbes, William P: 4 articles (01/2016 - 01/2015)|
|9.||Barrett, Andrew C: 4 articles (01/2016 - 01/2015)|
|10.||Becker, Gerhild: 4 articles (01/2013 - 11/2007)|
09/07/2008 - "Subcutaneous methylnaltrexone has recently been shown to be highly effective in the management of opioid-related constipation, and was recently approved by the FDA. "
10/01/2013 - "This case series suggests that methylnaltrexone is safe and may be effective when given subcutaneously as a 0.15 mg/kg single dose to pediatric oncology patients with opioid-induced constipation."
02/01/2012 - "Methylnaltrexone has been shown to be effective for treating opioid-induced constipation (OIC) in chronic settings, but its effects on acute OIC have not been studied. "
05/01/2011 - "Methylnaltrexone is effective for opioid-induced constipation (OIC) in advanced illness patients. "
01/01/2009 - "Methylnaltrexone appears effective in the therapy of opioid-induced constipation and will be useful for patients failing to respond to traditional laxative regimens."
05/01/2011 - "Although the efficacy of methylnaltrexone in reducing the duration of postoperative ileus was not demonstrated in these studies, intravenous methylnaltrexone at doses of 12 mg and 24 mg was safe, in general, and well tolerated in postcolectomy patients. "
01/01/2008 - "The intravenous formulation of methylnaltrexone is currently in phase III clinical trials for the potential treatment of postoperative ileus."
05/01/2011 - "The utility of intravenous methylnaltrexone in treating postoperative ileus remains unproven."
03/01/2011 - "Resolution of opioid-induced postoperative ileus in a newborn infant after methylnaltrexone."
05/01/2011 - "Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials."
08/01/2011 - "A post hoc analysis of a randomized, double-blind, placebo-controlled study evaluating patients with OIC and chronic nonmalignant pain who received 12 mg subcutaneous methylnaltrexone daily for 4 weeks was performed to determine if response to the first four methylnaltrexone doses predicted overall response during the study. "
05/07/2010 - "Methylnaltrexone was not associated with any significant changes in pain scores or central opioid withdrawal in these studies. "
08/01/2013 - "Also, clinical trial data of methylnaltrexone treatment in patients with OIC and other pain conditions (i.e., chronic noncancer pain and pain after orthopedic surgery) are reviewed. "
08/01/2012 - "Methylnaltrexone has a positive impact on symptoms in women with NBS, although treatment does induce transient pain following its administration. "
02/01/2012 - "Pain scores remained stable and were similar to those of placebo, and signs and symptoms of opioid withdrawal did not emerge in patients receiving methylnaltrexone. "
07/01/2015 - "Although methylnaltrexone is a successful treatment for OIC in adult cancer patients, no case series has established its safety and efficacy in pediatric cancer patients. "
07/01/2015 - "The aim of the study was to describe the safety and efficacy of methylnaltrexone use for OIC in children and AYA with progressive incurable cancer at the end of life in the inpatient and outpatient settings. "
07/01/2015 - "Methylnaltrexone appears to be safe and efficacious in treating OIC in children and AYA with progressive incurable cancer. "
07/01/2015 - "Of the 9 patients (age range: 17 months to 21 years) with progressive incurable cancer who developed OIC, 7 (78%) had laxation after methylnaltrexone administration (0.15 mg/kg/dose). "
07/01/2015 - "We conducted a retrospective review of medical records of children and AYA with progressive incurable cancer who received methylnaltrexone at our institution from May 2008 to June 2013. "
01/01/2016 - "The most common adverse events during methylnaltrexone treatment were abdominal pain (9.7% vs 1.5% for placebo) and nausea (5.2% vs 6.7%). "
04/16/2004 - "Our data suggest that methylnaltrexone has therapeutic value in treating opioid-induced nausea and vomiting."
01/01/1995 - "Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences."
05/01/2011 - "The primary and secondary efficacy outcomes (time to discharge eligibility, time to hospital discharge, and clinically meaningful events of nausea and vomiting following segmental colectomy) did not differ significantly between patients treated with either a dose of methylnaltrexone or with placebo. "
07/01/2015 - "Common adverse events were abdominal pain (pooled methylnaltrexone: 27.9%, placebo: 9.8%), flatulence (13.3%, 5.7%), and nausea (10.9%, 4.9%). "
|1.||mu Opioid Receptors (mu Opioid Receptor)
|3.||Opioid Receptors (Opioid Receptor)
|4.||Morphine (MS Contin)
|9.||Narcotic Antagonists (Opioid Antagonists)
|3.||Palliative Care (Palliative Medicine)